Nurse Anesthetist - CR in Taylor, TX Accepting Medicare

3 Nurse Anesthetist - CR nurses found. Showing 1 - 3

Donald J Hendryx, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: 305 Mallard Ln, Taylor, TX 76574 Phone: 512-352-7611    Fax: 512-352-4734

Bruce M Johns, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: 3645 Fm 3349, Taylor, TX 76574 Phone: 512-784-8071

Josef Cohen, Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 305 Mallard Ln, Taylor, TX 76574 Phone: 512-352-7611

News Archive

Yerkes researchers develop first transgenic nonhuman primate model of Huntington's disease

In the first study of its kind, researchers at the Yerkes National Primate Research Center, Emory University, in collaboration with researchers from the Department of Human Genetics at Emory's School of Medicine, have developed the first transgenic nonhuman primate model of Huntington's disease (HD), one of the most devastating human neurodegenerative diseases.

New research collaboration between EU and Russia focuses on infectious diseases

A new EU project on the theme of HIV, hepatitis C and tuberculosis is a door opener for collaboration between researchers from EU countries and Russia.

Study shows relation between mothers' income level and children's finger length

Low-income mothers feminize their children in the womb by adjusting their hormones, whereas high-income mothers masculinize their children, a major study based on finger length, led by a Swansea University expert, has found.

Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.

Pharmasset initiates PSI-7977 Phase 3 program for HCV

Pharmasset, Inc. today announced the initiation of a Phase 3 program with the hepatitis C virus (HCV) nucleotide analog, PSI-7977. This pivotal program will evaluate a 12-week, all-oral, interferon-free regimen of PSI-7977 and ribavirin in patients with HCV, independent of viral genotype or their ability to take interferon therapy.

Read more Medical News

› Verified 7 days ago